<DOC>
	<DOC>NCT00254137</DOC>
	<brief_summary>A randomized phase II-study to evaluate the safety and efficacy of capecitabine plus irinotecan plus cetuximab compared to capecitabine plus oxaliplatin plus cetuximab in first-line treatment of patients with metastatic colorectal cancer.</brief_summary>
	<brief_title>Cap/Iri Plus Cetuximab Compared to Cap/ox Plus Cetuximab in Patients With Metastatic Colorectal Cancer.</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Histologically confirmed metastatic colorectal cancer. EGFreceptor testing. No prior chemotherapy for colorectal cancer (except adjuvant chemotherapy with an interval ³ 6 months). No prior therapy with topoisomerase1 inhibitors, no prior therapy directed against the EGFpathway. No prior surgery (except diagnostic biopsy) or radiation therapy 4 weeks before start of study treatment. Measurable disease (diameter ³ 20mm, diameter ³ 10mm with spiralCT). Male and female patients ³ 18 years, £ 75 years. Karnofsky PS ³ 70%. Life expectancy ³ 3 months. Effective contraception if risk of conception exists. Adequate bone marrow, liver and renal function (leucocytes ³3.000/µl, neutrophils ³1.500/µl, platelets ³100.000/µl, hemoglobin ³9g/dl, bilirubin £1,5x ULN, ASAT and ALAT £3x ULN (£5x ULN with liver metastasis), serum creatinine £1,5x ULN). Written informed consent. Concurrent treatment of colorectal cancer (except study medication). EGFreceptor testing not possible. Known DPDdeficiency (no particular screening necessary). Known GilbertMeulengrachtSyndrome (no particular screening necessary). Known or expected contraindication against study medication. Participation in other studies during 30 days before study entry. Prior myocardial infarction, severe renal insufficiency (creatinine clearance £30ml/min). Previous malignancy (except colorectal cancer, history of basal cell carcinoma of skin or preinvasive carcinoma of the cervix with adequate treatment and no sign of disease during 5 years). Known or suspected cerebral metastasis. History of inflammatory bowel disease. Symptomatic peritoneal carcinomatosis. Drug or alcohol abuse. Lack of adequate legal capacity. Breastfeeding or pregnant women. Concurrent medication with Sorivudine and analoga, anticoagulation with Cumarine or derivatives.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2004</verification_date>
	<keyword>capecitabine</keyword>
	<keyword>irinotecan</keyword>
	<keyword>cetuximab</keyword>
	<keyword>oxaliplatin</keyword>
	<keyword>colorectal cancer</keyword>
</DOC>